Clarity Pharmaceuticals (ASX:CU6) Moat Score: 4/10 (As of Jun. 29, 2026)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$2.10
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Moat Score?

Clarity Pharmaceuticals ASX:CU6 +15.70% 39 Moat Score is 4 as of Jun. 29, 2026. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, Clarity Pharmaceuticals ranks better than 88.79% on this metric.

Clarity Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Clarity Pharmaceuticals has Narrow Moat: Clarity Pharmaceuticals Ltd has valuable intellectual property in the form of patents, providing some protection. However, the pharmaceutical industry is competitive, and while there are regulatory barriers, the company's market share and brand strength are modest.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Clarity Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

Clarity Pharmaceuticals  (ASX:CU6) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Clarity Pharmaceuticals Moat Score Related Terms

ASX:CU6 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Clarity Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Moat Score falls into.


ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Clarity Pharmaceuticals (ASX:CU6) has a Moat Score of 4 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Clarity Pharmaceuticals ranks #157 out of 1401 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Clarity Pharmaceuticals' Moat Score too high?
Clarity Pharmaceuticals' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Clarity Pharmaceuticals' value of 4 is 100% above this industry median. Based on the distribution chart, Clarity Pharmaceuticals ranks #157 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #157 out of 1401 companies for Moat Score. This places Clarity Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Clarity Pharmaceuticals' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clarity Pharmaceuticals's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clarity Pharmaceuticals's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Moat Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.10
Price